InvestorsHub Logo

hooperg83

11/15/15 8:25 PM

#36831 RE: orveko_inc #36825

Great catch. I'll fix that up quickly for the SA contribution.

stealthways

11/16/15 9:25 AM

#36896 RE: orveko_inc #36825

Basically, A2-73's agonism of sigma-1 and M1 receptors may work to alter the progression of AD, while its antagonism of the M2 and M3 receptors may work to improve the affects of donepezil on the symptoms of the disease.



nice simple summary Oreveko.....